Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study

Jaehyun Bae1,*, Min Jung Lee2,*, Eun Yeong Choe3, Chang Hee Jung4, Hye Jin Wang4, Myoung Soo Kim5, Yu Seun Kim5, Joong-Yeol Park2, Eun Seok Kang1,6

1Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul; 2Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul; 3Division of Endocrinology, Department of Internal Medicine, International St. Mary’s Hospital, Catholic Kwandong University College of Medicine, Incheon; 4Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul; 5Department of Transplantation Surgery, Yonsei University Health System, Seoul; 6Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea

Background: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes.

Methods: Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor.

Results: HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40%±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin.

Conclusion: Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes.

Keywords: Dipeptidyl-peptidase IV inhibitors; Sitagliptin phosphate; Vildagliptin; Linagliptin; Cyclosporine; Kidney transplantation; Diabetes mellitus
INTRODUCTION

Kidney transplantation (KT) has become the treatment of choice for end-stage renal disease [1]. With modern advances in surgical techniques and immunosuppressant medications, life expectancy following KT has increased [1] and controlling chronic metabolic complications such as diabetes mellitus is considered an important medical issue [2].

Dipeptidyl peptidase-4 (DPP-4) inhibitors are new oral glucose-lowering agents that prevent the inactivation of glucagon-like peptide-1 and stimulate insulin secretion in a glucose-dependent manner [3]. Because the efficacies of DPP-4 inhibitors for reducing blood glucose have been demonstrated by multiple clinical trials [3,4], a rapid increase in their clinical use is anticipated [5]. Although different DPP-4 inhibitors showed similar glucose-lowering efficacies [5], they demonstrated various metabolic and excretory properties. Some are metabolized by the cytochrome P450 3A system [6], and their intestinal absorption and renal excretion might be affected by P-glycoprotein, an efflux transporter involved in the absorption and/or elimination of the drug [7].

Cyclosporine is a calcineurin inhibitor and immunosuppressive agent that is widely used in organ transplants and some autoimmune diseases [8,9]. However, they have a narrow therapeutic window, and levels below this window are associated with an increased risk for rejection, whereas levels above the window are correlated with side effects such as nephrotoxicity, neurotoxicity, hepatotoxicity, and hypertension [10]. Furthermore, because cyclosporine is mainly metabolized in the liver by the cytochrome P450 3A system, as well as P-glycoprotein substrates [11], various compounds that induce or inhibit the cytochrome P450 3A system or P-glycoprotein may influence the trough concentrations of cyclosporine [12,13].

Although the concurrent use of DPP-4 inhibitors and immunosuppressants are expected to increase among organ transplant patients with diabetes mellitus, the glucose-lowering efficacy of various DPP-4 inhibitors and their effects on the concentrations of calcineurin inhibitors have not been fully investigated.

In our current study, we compare the glucose-lowering efficacies of three different DPP-4 inhibitors (vildagliptin, sitagliptin, and linagliptin) and evaluate their effects on the trough levels of cyclosporine in KT recipients with diabetes mellitus.

METHODS

Study subjects

We conducted the retrospective, longitudinal, observational study on patients who underwent KT between 2000 and 2013 at Yonsei University Health System (Seoul, Korea) or Asan Medical Center (Seoul, Korea). Among them, renal allograft recipients with diabetes who initiated treatment with DPP-4 inhibitor (vildagliptin, sitagliptin, and linagliptin) after transplantation were enrolled in this study. All KT recipients in both hospital received triple maintenance therapy which was composed of cyclosporine, mycophenolate mofetil or azathioprine, and corticosteroid. All study patients survived >12 months after transplant.

Lifestyle factors and measurements

Height (m) and weight (kg) were measured while each patient was wearing light clothing without shoes. Body mass index (kg/m^2) was calculated as weight in kilograms divided by the square of height in meters. Patients with diabetes were defined as those with a fasting plasma glucose (FPG) \(\geq 7.0 \text{ mmol/L} \), hemoglobin A1c (HbA1c) \(\geq 6.5\%\), and/or receiving antidiabetic medications at 1 year after transplantation.

After overnight fasting, blood samples were drawn from the antecubital vein in the early morning. Fasting total cholesterol, high-density lipoprotein cholesterol, low density lipoprotein cholesterol, and triglyceride levels were measured using the enzymatic colorimetric method (Toshiba Medical System Co., Tokyo, Japan). FPG concentrations were measured using enzymatic colorimetric hexokinase (Toshiba Medical System Co.) methods on the Hitachi 7600 system (Hitachi Co., Tokyo, Japan).

HbA1c was measured using the immunoturbidimetric method on the Cobas Integra 800 System (Roche Diagnostics, Basel, Switzerland). Follow-up HbA1c values were measured after 3 months of treatment with the DPP-4 inhibitors. This system is standardized by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC); however, National Glycohemoglobin Standardization Program (NGSP) approved this measuring system. This machine automatically converts mmol/mol (IFCC) into % (NGSP).

Cyclosporine trough levels were measured by immunoassay methods using the Dimension EXL 200 Integrated Chemistry System (Asan Medical Center) or the Affinity Column Mediated Immunoassay method using the Dimension RXL Max (Yonsei University Health System). Venous samples were drawn 12 hours after the last dose (i.e., immediately before the next dose) in order to measure the trough levels. Changes in the serum cyclosporine trough levels after 2 months treatment were also assessed. Creatinine was measured using the Jaffe method, and the estimated glomerular filtration rate was calculated using the
Modification of Diet in Renal Disease study equation [14].

Statistical analysis
Continuous variables with normal distributions are expressed as the mean ± standard deviation. Categorical variables are expressed as percentages (%). The characteristics of the study population (according to the type of DPP-4 inhibitor) were compared using one-way analysis of variance for continuous variables, or the chi-square test for categorical variables. The post hoc analysis was performed using Scheffe’s method. Follow-up HbA1c values were measured after 3 months of treatment with the DPP-4 inhibitor and compared with the baseline values using paired t tests. All statistical analyses were performed using SPSS version 19.0 (IBM Co., Armonk, NY, USA). P values < 0.05 were considered statistically significant.

RESULTS
Sixty-five patients who initiated treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, and linagliptin) after KT were analyzed. Twenty-five of these patients underwent KT at Yonsei University Health System, 40 patients underwent KT at Asan Medical Center. The mean age at the initiation of DPP-4 inhibitor was 52.05 ± 9.76 years, and the mean duration of diabetes

Table 1. Characteristics of Patients and the Effect of DPP-4 Inhibitors on HbA1c

| Variable                                      | Vildagliptin (n=17) | Sitagliptin (n=28) | Linagliptin (n=20) | P value |
|-----------------------------------------------|---------------------|--------------------|--------------------|---------|
| Age at KT, yr                                 | 50.71 ± 12.32       | 52.29 ± 8.53       | 45.00 ± 8.15       | 0.035   |
| Age at treatment of DPP-4 inhibitors, yr      | 52.53 ± 13.04       | 54.14 ± 8.05       | 48.70 ± 8.19       | 0.159   |
| Time between KT and DPP-4 inhibitor initiation, yr | 1.82 ± 3.00         | 1.86 ± 3.31        | 3.70 ± 4.24        | 0.160   |
| Sex, male:female                              | 12:05               | 18:10              | 8:12               | 0.121   |
| Body mass index, kg/m²                        | 22.87 ± 3.69        | 23.42 ± 2.40       | 24.08 ± 3.60       | 0.512   |
| Duration of diabetes, yr                      | 5.46 ± 5.55         | 9.70 ± 7.76        | 8.38 ± 9.17        | 0.315   |
| Baseline creatinine, mg/dL                    | 1.32 ± 0.29         | 1.12 ± 0.30        | 1.16 ± 0.39        | 0.125   |
| Follow-up creatinine, mg/dL                   | 1.41 ± 0.95         | 1.22 ± 0.82        | 1.25 ± 0.42        | 0.265   |
| Baseline eGFR, mL/min/1.73 m²                 | 60.68 ± 13.19       | 69.32 ± 17.85      | 66.08 ± 25.65      | 0.364   |
| Follow-up eGFR, mL/min/1.73 m²                | 58.21 ± 17.76       | 61.03 ± 16.50      | 62.82 ± 18.74      | 0.160   |
| Fasting plasma glucose, mg/dL                 | 134.88 ± 45.01      | 139.00 ± 51.92     | 142.90 ± 63.40     | 0.904   |
| Postprandial glucose, mg/dL                   | 201.75 ± 55.26      | 211.00 ± 78.14     | 290.0 ± 135.63     | 0.207   |
| Baseline HbA1c, %                             | 7.57 ± 2.11         | 7.76 ± 1.53        | 8.11 ± 1.29        | 0.578   |
| After treatment HbA1c, %                      | 7.08 ± 1.81         | 7.18 ± 1.21        | 6.79 ± 0.63        | 0.561   |
| Difference of HbA1c (ΔHbA1c), %               | -0.38 ± 1.03        | -0.53 ± 0.95       | -1.40 ± 1.34       | 0.016   |
| Total cholesterol, mg/dL                      | 193.49 ± 35.09      | 215.31 ± 76.16     | 196.42 ± 54.56     | 0.420   |
| Triglyceride, mg/dL                           | 165.82 ± 90.73      | 164.96 ± 103.88    | 170.50 ± 66.56     | 0.981   |
| HDL-C, mg/dL                                  | 46.06 ± 11.55       | 57.35 ± 18.78      | 56.75 ± 15.91      | 0.068   |
| LDL-C, mg/dL                                  | 114.12 ± 22.89      | 126.55 ± 57.10     | 115.48 ± 47.92     | 0.635   |
| Dose of DPP-4 inhibitor, %                    |                     |                    |                    | <0.001  |
| Full dose                                      | 67.7                | 95.3               | 100                |         |
| Reduced dose                                   | 32.3                | 4.7                | -                  |         |
| Antidiabetic medication, %                    |                     |                    |                    | 0.067   |
| DPP-4 inhibitor only                           | 9.2                 | 7.8                | 27.6               |         |
| DPP-4 inhibitor+other OHA                      | 87.7                | 90.6               | 69.0               |         |
| DPP-4 inhibitor+insulin                        | 3.1                 | 1.6                | 3.4                |         |

Values are expressed as mean ± SD.
DPP-4, dipeptidyl peptidase-4; HbA1c, hemoglobin A1c; KT, kidney transplantation; eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; OHA, oral hypoglycemic agent.

*Post hoc analysis using Scheffe’s method was used to compare ΔHbA1c (vildagliptin vs. sitagliptin, P= no significant difference; vildagliptin vs. linagliptin, P= 0.039; sitagliptin vs. linagliptin, P= 0.036); † A full dose of vildagliptin was 50 mg twice daily and sitagliptin was 100 mg once daily; ‡ A reduced dose of vildagliptin and sitagliptin was 50 mg once daily.
was 8.14 ± 7.80 years.

Table 1 shows the clinical and biochemical characteristics of the patients according to the type of DPP-4 inhibitor administered at baseline. Subjects in sitagliptin group were slightly older at the KT than other DPP-4 inhibitor groups (P = 0.049). Age at DPP-4 inhibitor initiation was not different among the groups. According to renal function, sitagliptin and vildagliptin doses were adjusted. Both agents were treated with 50 mg once daily in renal insufficient patients. All of the patients in linagliptin group received full dose DPP-4 inhibitor medication. Concurrent anti-diabetic medications were similar among the groups.

The HbA1c values measured 3 months after treatment with DPP 4 inhibitors were significantly lower in comparison with baseline in all groups (Table 1). When we compared glucose lowering efficacy of DPP-4 inhibitors through the changes in HbA1c from baseline to 3 months of treatment, the levels of HbA1c decreased significantly in the linagliptin group compared with other DPP-4 inhibitor groups (vildagliptin –0.38% ± 1.03%, sitagliptin –0.53% ± 0.95%, and linagliptin –1.40 ± 1.34; P = 0.016). Even after excluding the patients receiving insulin therapy, the level of HbA1c significantly decreased in the linagliptin group (data not shown).

Although there were no differences in baseline cyclosporine doses and blood levels, cyclosporine trough levels were significantly increased in the sitagliptin group (30.62 ± 81.70 ng/mL) in comparison with the vildagliptin group (–24.22 ± 53.54 ng/mL, P = 0.031) (Table 2, Fig. 1). Cyclosporine trough levels were minimally changed in patients with linagliptin (–8.50 ± 54.35 ng/mL). There was no difference of change in cyclosporine dose among the three groups (P = 0.411) (Table 2, Fig. 1).

DISCUSSION

In this observational longitudinal study, we found that linagliptin showed a better glucose-lowering efficacy in comparison with other DPP-4 inhibitors in renal allograft recipients with type 2 diabetes. Furthermore, after 2 months of treatment with DPP-4 inhibitors, patients in the sitagliptin group demonstrated increased serum cyclosporine trough levels in comparison with the vildagliptin group.

Hyperglycemia is associated with adverse long-term outcomes in renal allograft recipients with diabetes [15-17], and glycemic control is an important factor for preventing allograft loss [16] and reducing patient mortality [17]. Recent data demonstrated that impaired insulin secretion, rather than increased insulin resistance, played an important role in the development of diabetes in KT recipients [18], which indicated that the anti-

Table 2. Changes in Administered Doses and Trough Levels of Cyclosporine after 2 Months’ Treatment of Dipeptidyl Peptidase-4 Inhibitors

| Variable                        | Vildagliptin | Sitagliptin | Linagliptin | P value |
|---------------------------------|--------------|-------------|-------------|---------|
| Baseline cyclosporine dose, mg/day | 172.06±91.81 | 175.89±102.40 | 136.25±66.13 | 0.291   |
| Follow-up cyclosporine dose, mg/day | 147.06±61.16 | 155.36±54.16 | 131.25±60.63 | 0.369   |
| Change in cyclosporine dose, mg/day | –25.00±40.50 | –20.54±65.99 | –5.00±15.39 | 0.411   |
| Baseline cyclosporine trough level, ng/mL | 143.78±76.90 | 136.33±60.58 | 114.98±60.96 | 0.368   |
| Follow-up cyclosporine trough, ng/mL | 119.56±58.44 | 159.14±90.41 | 106.19±69.57 | 0.064   |
| Change in cyclosporine trough level, ng/mL | –24.22±53.54a | 30.62±81.70b | –8.50±54.35ab | 0.023   |

Values are expressed as mean±SD. Post hoc analysis of cyclosporine trough level using (Scheffe’s method-vildagliptin vs. sitagliptin, P=0.036; vildagliptin vs. linagliptin, P=0.780; sitagliptin vs. linagliptin, P=0.149).

a,bSame letters indicate no significant differences between groups.

Fig. 1. Change in cyclosporine trough level. *Vildagliptin vs. sitagliptin, P=0.036; vildagliptin vs. linagliptin, P=0.780; sitagliptin vs. linagliptin, P=0.149.
diabetic agents that preserve or even improve pancreatic β-cell function may be beneficial for glycemic control in organ transplant patients [18]. In previous studies, DPP-4 inhibitors demonstrated protective effects toward pancreatic β-cell survival [19,20]. Furthermore, because several studies showed that DPP-4 inhibitors can be safely administered to patients with renal insufficiency at low risk for hypoglycemia [3,21], increasing use of these medications in KT patients is expected.

Various DPP-4 inhibitors showed similar efficacies in terms of lowering HbA1c [5], but their metabolism and excretion demonstrated widely variable properties [6]. Sitagliptin is primarily eliminated in an unchanged form in the urine (79%), and a relatively small portion is metabolized by the hepatic cytochrome P450 3A4 and 2C8 systems [22]. Vildagliptin is extensively metabolized by multiple pathways that are not mediated by cytochrome P450 enzymes [23], and about two-thirds of the drug is excreted as a metabolite through the kidneys [24]. Vildagliptin did not alter the pharmacokinetic of other drugs using P-glycoprotein–mediated transport system [24]. Linagliptin is mainly eliminated in an unchanged form via the feces (84.7%), and renal excretion only accounts for 5.4% of elimination [25].

In our study, linagliptin significantly reduced HbA1c levels in comparison with other DPP-4 inhibitors over the 3-month follow-up period. Furthermore, serum cyclosporine trough levels increased significantly in the sitagliptin group, even though the administered doses of cyclosporine were decreased for 2 months. Cyclosporine is extensively metabolized in the liver by the cytochrome P450 3A system [12], but the DPP-4 inhibitors compared in our present study are not known as inhibitors or inducers of the cytochrome 450 system [6]. Thus, the different effects of the DPP4-inhibitors on blood cyclosporine trough levels might not be explained by the drug interactions that are mediated by the cytochrome P450 system. Recently, clinically significant drug interactions mediated by P-glycoprotein have been described [11]. P-glycoprotein is an efflux transporter found in the enterocytes, hepatocytes, and renal tubular cells [11,26]. Regarding the drug interactions between sitagliptin and cyclosporine, Krishna et al. [27] reported that the sitagliptin AUC<sub>0-∞</sub> (area under the concentration-time curves from time zero to infinity) increased in healthy male participants due to the inhibitory effects of cyclosporine on intestinal P-glycoprotein. Considering that both sitagliptin and cyclosporine are substrates and inhibitors of P-glycoprotein [6,27,28], sitagliptin might inhibit intestinal P-glycoprotein in a competitive or non-competitive manner and promote the absorption of cyclosporine, which in turn increases serum cyclosporine trough levels.

Our study had limitations. First, we did not perform a formal pharmacokinetic study, which requires drawing multiple blood samples over the dosing interval. Thus, the trough levels of the calcineurin inhibitors might not have accurately reflected the AUC<sub>0-24</sub> values. Second, we only checked the HbA1c and cyclosporine levels at the baseline visit and at the first follow-up visit. Additional measures at multiple time points should make the conclusion more definite. Although dose of cyclosporine had changed with therapeutic dose monitoring within 2 months and dose of cyclosporine was not different among the DPP-4 inhibitor groups, statistically insignificant change in cyclosporine dose could affect the blood cyclosporine levels. However, our study, as a pilot study, has robust feature in that we first compared the glucose-lowering efficacy of DPP-4 inhibitors in renal allograft recipients and evaluated their effects on the blood concentrations of cyclosporine levels.

In conclusion, we found in this pilot study that linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough level in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes. In addition, patients who receive sitagliptin demonstrated significantly increased cyclosporine trough levels through 2 months of treatment. However larger study and follow up study are warranted to get definite conclusion.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This work was financially supported by the “Kiturami” Faculty Research Assistance Program of Yonsei University College of Medicine (no. 6-2012-0148) and the National Research Foundation of Korea, which is funded by the Korean Government (MEST Basic Research Promotion Fund; nos. NRF-2010-013-E0008 and NRF-2012000891).

ORCID

Eun Seok Kang http://orcid.org/0000-0002-0364-4675

REFERENCES

1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J
Med 1994;331:365-76.
2. Schiel R, Heinrich S, Steiner T, Ott U, Stein G. Long-term prognosis of patients after kidney transplantation: a comparison of those with or without diabetes mellitus. Nephrol Dial Transplant 2005;20:611-7.
3. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-84.
4. Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009;76 Suppl 5:S28-38.
5. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011;34 Suppl 2:S276-8.
6. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58.
7. Fuchs H, Runge F, Held HD. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. Eur J Pharm Sci 2012;45:533-8.
8. Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 1984;101:667-82.
9. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007;2:374-84.
10. Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998;31:309-16.
11. Lin JH. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 2007;3:81-92.
12. Christians U, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 1995;28:547-59.
13. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
15. Valderhaug TG, Hjelmesæth J, Hartmann A, Roislien J, Bergrem HA, Leivestad T, et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011;54:1341-9.
16. Thomas MC, Mathew TH, Russ GR. Glycaemic control and graft loss following renal transplantation. Nephrol Dial Transplant 2001;16:1978-82.
17. Wiesbauer F, Heinze G, Regele H, Horl WH, Schernthaner GH, Schwarz C, et al. Glucose control is associated with patient survival in diabetic patients after renal transplantation. Transplantation 2010;89:612-9.
18. Hecking M, Kainz A, Werzowa J, Haidinger M, Doller D, Tura A, et al. Glucose metabolism after renal transplantation. Diabetes Care 2013;36:2763-71.
19. Hamamoto S, Kanda Y, Shimoda M, Tatsumi F, Kohara K, Tawaramoto K, et al. Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes Metab 2013;15:153-63.
20. Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. J Endocrinol 2012;214:381-7.
21. Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf 2011;6:304-9.
22. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321:673-83.
23. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88.
24. He YL, Sabo R, Sunkara G, Bizot MN, Riviere GJ, Leon S, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007;47:998-1004.
25. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010;38:667-78.
26. Koziolek MJ, Riess R, Geiger H, Thevenod F, Hauser IA. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2001;60:156-66.
27. Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Ditzer S, et al. Effect of a single cyclosporine dose on the single-
dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 2007;47:165-74.

28. Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Meria P, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006;70:1019-25.